Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs(Emma Kinderziekenhuis), John C. Lieske(Mayo Clinic), William G. van’t Hoff(Université Claude Bernard Lyon 1), Kristin Meliambro(Icahn School of Medicine at Mount Sinai), Jiandong Lu(Guangzhou University of Chinese Medicine), David J. Sas(Mayo Clinic), Georges Deschênes(Hôpital Robert-Debré), Michael J. Koren(Jacksonville Center for Clinical Research), Gesa Schalk, Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), John M. Gansner(Brigham and Women's Hospital), Pierre Cochat(Société Nationale des Chemins de Fer Français (France)), Daniel G. Fuster(University Hospital of Bern), Eva Šimková(Université Claude Bernard Lyon 1), Jeffrey M. Saland(Université Claude Bernard Lyon 1), Yaacov Frishberg(Shaare Zedek Medical Center), Pushkal Garg(Université Paris-Sud), Akshay Vaishnaw(Alnylam Pharmaceuticals (United States)), Daniella Magen(Université Claude Bernard Lyon 1), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), William O’Riordan(Université Paris-Sud), Sally A. Hulton(Birmingham Children's Hospital), Marianne T. Sweetser(Alnylam Pharmaceuticals (United States)), Tracy L. McGregor(Université Claude Bernard Lyon 1), Jaap W. Groothoff(University of Amsterdam)
Cited by 505
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
|New England Journal of Medicine|2013|961
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712